Heart failure & cardiomyopathies
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF
Authors' conclusion
In the FINEARTS-HF trial, finerenone reduced the primary outcome and components of the primary outcome and improved symptoms across a wide age spectrum. In addition, finerenone was safe and well-tolerated, irrespective of age.
Study context
- Population
- Patients with HF with mildly reduced or preserved EF, aged 40 to 97 years, stratified by baseline age quartile4 age quartiles
- Participants
- 6,001 patients
- Comparison
- Finerenone vs placebo, by age quartile
- Primary endpoint
- Composite of:
- CV death
- Total (first and recurrent) HF events (HF hospitalization or urgent HF event)
Methodological detailsprespecified analysis, placebo-controlled
- Prespecified analysis
- Placebo-controlled
Primary result
As reported in the abstract
Finerenone vs PlaceboRate ratio (95% CI)
Q1, 40 to 66 years (n=1581)
0.70(0.53–0.92)
Q2, 67 to 73 years (n=1587)
0.83(0.64–1.07)
Q3, 74 to 79 years (n=1421)
0.98(0.76–1.26)
Q4, ≥80 years (n=1412)
0.85(0.67–1.07)
Secondary outcomes
| Outcome | Mean placebo-corrected change (95% CI) | |
|---|---|---|
| KCCQ total symptom score change, by age quartile · baseline to 12 monthsFinerenonevs PlaceboQ1 | 2.87 (1.09–4.66) | |
| KCCQ total symptom score change, by age quartile · baseline to 12 monthsFinerenonevs PlaceboQ2 | 1.24 (−0.59 to 3.07) | |
| KCCQ total symptom score change, by age quartile · baseline to 12 monthsFinerenonevs PlaceboQ3 | 0.94 (−0.98 to 2.86) | |
| KCCQ total symptom score change, by age quartile · baseline to 12 monthsFinerenonevs PlaceboQ4 | 1.24 (−0.90 to 3.38) | |
| −20246Difference (linear scale) |
- KCCQ total symptom score change, by age quartile: interaction P=0.50
Components of the primary outcome, by age
- Consistent effect across age categories
Safety
- Adverse events similar across age categories; odds of hypotension, elevated creatinine, hyperkalemia or hypokalemia did not differ by age
Original publication
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF. Circ Heart Fail. Published 29 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →